ARTICLE | Product Development

Triple Threat in IPF

Boehringer hopes its triple kinase inhibitor can improve outcomes in IPF

November 22, 2010 8:00 AM UTC

As the understanding of idiopathic pulmonary fibrosis has grown, it's becoming clearer that a variety of growth factors and proteins contribute to development of the disease. Boehringer Ingelheim GmbH believes data from a Phase II trial show that targeting multiple growth factors with its triple kinase inhibitor, BIBF 1120, can lead to better clinical outcomes.

The question now is how to move it forward...